Frank G. Moody, M.D., who helped battle obesity in the 1970s by promoting weight loss surgery, has been honored by the American Surgical Association (ASA). He is a professor at John P. and Kathrine G. McGovern Medical School at UTHealth.
A multi-institutional collaboration, including The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, has been awarded a $1.3 million training grant from the National Institute of Environmental Health Sciences (NIEHS) to fund the Biosafety and Infectious Disease Training Initiative.
Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a new clinical research collaboration to evaluate innovative strategies for the potential use of Bristol-Myers Squibb’s immuno-oncology agents Opdivo (nivolumab) and Yervoy (ipilimumab) to treat early- and advanced-stage lung cancer patients.
Lung cancer patients with oliogometastases, defined as three or fewer sites of metastasis, may benefit from aggressive local therapy, surgery or radiation, after standard chemotherapy, according to research led by The University of Texas MD Anderson Cancer Center.
Advances that could change gynecologic cancer standard–of-care treatments are the centerpiece of key studies being presented by researchers from The University of Texas MD Anderson Cancer Center’s Department of Gynecologic Oncology and Reproductive Medicine at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO).
The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug’s target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.
In the first-ever clinical trial for metastatic patients previously treated for the disease, research led by The University of Texas MD Anderson Cancer Center found that the immune checkpoint blockade nivolumab shows promise for the majority of patients with squamous cell carcinoma of the anal canal (SCCA).
Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research from The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® seminar to Raleigh, N.C., for the first time, 11:30 a.m. to 1 p.m., Wednesday, June 8, at the McKimmon Conference and Training Center, 1101 Gorman St. Renowned experts from the nation’s No. 1 hospital for cancer care will share recent developments in cancer research, care and prevention.
Researchers at The University of Texas Health Science Center at Houston (UTHealth) plan to launch a clinical study looking at complication rates in patients who have experienced severe trauma to the abdominal area and require immediate surgery to diagnose and treat the injuries at Memorial Hermann-Texas Medical Center.
Researchers at The University of Texas MD Anderson Cancer Center have discovered mutations that may fuel early cancer growth in precancerous colorectal tissue from high-risk patients.
Exposure to e-cigarette marketing messages is significantly associated with e-cigarette use among middle school and high school students, according to researchers at The University of Texas Health Science Center at Houston (UTHealth).
Ionis Pharmaceuticals, Inc.,and The University of Texas MD Anderson Cancer Center today announced the formation of a strategic alliance to discover and develop novel cancer therapeutics.
The University of Texas MD Anderson Cancer Center will receive $10.6 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT) for two collaborative studies targeting crucial issues in lung cancer.
Harris Health System has received a hallmark accreditation for its comprehensive cancer programs listing it among the elite cancer institutions nationally that treat cancer as a complex group of diseases and has achieved improved patient care.
The New York Life Foundation has awarded a three-year, $1.55 million grant to the UTHealth Trauma and Grief (TAG) Center for Youth to establish a multi-site practice-research network that will refine, evaluate and validate assessment tools for grieving children to identify the appropriate support or intervention needed.
In Houston, African-American adults comprise 19 percent of the population, but account for about 34 percent of hospital admissions and are roughly three times more likely to die from asthma. For this reason, Harris Health System and Baylor College of Medicine are conducting a $2.3 million study to help asthmatics control and manage their condition.
Harris Health System has again earned the CEO Cancer Gold Standard by the CEO Roundtable on Cancer for its efforts to reduce the risk of cancer for its employees and covered family members. The health system is one of five other hospital systems in Texas to receive the coveted recognition.
Chronic use of some drugs for heartburn and gastroesophageal reflux (GERD) speeds up the aging of blood vessels, according to a published paper in Circulation Research (early online), an American Heart Association journal. This accelerated aging in humans could lead to increased cardiovascular disease, vascular dementia and renal failure.
It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
A study comprised of 39 international institutions revealed significant new findings about adrenocortical carcinoma (ACC), a rare cancer with an often poor prognosis.
The University of Texas MD Anderson Cancer Center fully supports new rules issued by the Food and Drug Administration (FDA) today to extend federal regulatory authority to all tobacco products, including electronic cigarettes, cigars, hookah and other previously unregulated tobacco products.
A study providing new information about neuropathic pain afflicting some 90 percent of cancer patients who have had nerve damage caused by tumors, surgery, chemotherapy or radiation indicates gene therapy as a possible treatment.
Small, non-coding molecules called microRNAs are known to play an important role in cancer development. Researchers now have shown their significance is greater than previously thought, a finding that could lead to new therapeutic approaches for the most common and deadly form of ovarian cancer.
Screening women for osteoporosis is now routine, however, when it comes to men, most are never screened and therefore suffer the consequences of the disease. In the U.S., nearly 1.5 million men over 65 have osteoporosis, and another 3.5 million men are at risk for developing the disease.
Cytopathology researchers at Houston Methodist Hospital recently found that combining two diagnostic tests, Pap and high-risk human papillomavirus (hrHPV), dramatically decreased the chance of missing tumors and high-grade lesions by sevenfold.
A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by The University of Texas MD Anderson Cancer Center.
The neonatal intensive care unit for sickest of newborns at Harris Health System’s Ben Taub Hospital is the only Gold Level recipient of the Beacon Award for Excellence in Texas. The prestigious designation is awarded to hospitals with exceptional patient care and is given by the American Association of Critical-Care Nurses.
The University of Texas MD Anderson Cancer Center and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, today announced that they signed a strategic alliance on a broad, multi-years program of clinical studies in cancer supportive and palliative care.
The University of Texas MD Anderson Children’s Cancer Hospital, in collaboration with local restaurants and businesses, will host a special prom for its pediatric cancer patients on Saturday, April 30 from 5 p.m. to 9 p.m.
Eight of The University of Texas MD Anderson Cancer Center’s top young researchers today were formally named Andrew Sabin Family Fellows at an event honoring their benefactor, Andrew Sabin, and representatives of the Andrew Sabin Family Foundation.
Scientists may have discovered a significant new diagnostic marker for liver cancer, according to a paper published in the April 18 online issue of Nature Cell Biology.
Researchers at The University of Texas MD Anderson Cancer Center have announced a new method for detecting DNA mutations in a single cancer cell versus current technology that analyzes millions of cells which they believe could have important applications for cancer diagnosis and treatment. The results are published in the April 18 online issue of Nature Methods.
A phase I study of the drug LOXO-101 appears to significantly reduce tumors in patients with varied types of genetically defined cancer, according to a study led by The University of Texas MD Anderson Cancer Center.
A rare malignancy known as squamous cell carcinoma of the anal canal (SCCA) is on the increase, and now researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab.
Waun Ki Hong, M.D., professor of Thoracic Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, has been selected as recipient of this year’s Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research by the American Association for Cancer Research (AACR).
The University of Texas MD Anderson Cancer Center and Saks Fifth Avenue will join forces April 27 at a cocktail and store preview event to celebrate the recent Saks Fifth Avenue move within the all-new Galleria III. Saks Fifth Avenue is contributing 100 percent of ticket sales and 10 percent of the evening’s store sales to benefit MD Anderson’s Moon Shots Program, an unprecedented effort to rapidly reduce deaths from cancer and transform care.
Long associated with liver cancer and non-Hodgkin’s lymphoma, a study from The University of Texas MD Anderson Cancer Center reveals for the first time that the hepatitis C virus (HCV) is associated with certain head and neck cancers.
A compound enriched in citrus peels strengthens the body clock and protects against metabolic syndrome in mice, according to a study led by scientists at The University of Texas Health Science Center at Houston (UTHealth).
Receptors for leptin, a protein hormone, may be associated with tumor recurrence in patients with renal cell carcinoma (RCC), providing further understanding about molecular links between obesity and RCC tumor formation and prognosis, according to a study at The University of Texas MD Anderson Cancer Center.
UT Physicians, the medical practice of McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), has opened its newest health center, UT Physicians Community Health & Wellness Center – Victory at 7364 Antoine Drive.
The University of Texas MD Anderson Cancer Center welcomed His Highness Sheikh Hamed Bin Zayed Al Nahyan, Chairman of the Crown Prince Court of Abu Dhabi, and His Excellency Mohamed Haji Al Khoori, Director General of the Khalifa Bin Zayed Al Nahyan Foundation, April 8 to celebrate the dedication of the Sheikh Zayed Bin Sultan Al Nahyan Building for Personalized Cancer Care.
The Houston Methodist Research Institute’s newly created Center of Space Nanomedicine is working with the Center for the Advancement of Science in Space (CASIS) to send eight experiments to the International Space Station (ISS) over the next five years. The first experiment is set for launch this week.
Allergy season can be the worst time of year for people suffering with restless legs syndrome because popular over the counter medications can make symptoms much worse.
TESARO, Inc., an oncology focused biopharmaceutical company, and the Institute for Applied Cancer Science at The University of Texas MD Anderson Cancer Center today announced an exclusive collaboration to discover and develop small molecule product candidates against undisclosed immuno-oncology targets.
The University of Texas MD Anderson Cancer Center’s Volunteer Endowment for Patient Support (VEPS), which funds patient-focused programs, celebrates its 25th anniversary this year.
Millions of Americans suffer ventral hernias, conditions that require surgery to repair. However, about 30 percent of patients require a second procedure to fully repair a hernia. To improve the odds of success for an initial surgery, physicians and staff at Harris Health System and the University of Texas Health Science Center at Houston (UTHealth) are testing to see if patients assigned a guided pre-surgical program of weight management and exercise tolerance makes a difference. If so, the rate of follow-up repairs would decrease and an improvement in a patient's quality of life could be realized.
The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® seminar to Austin, 11:30 a.m. to 1 p.m., Tuesday, April 19, at the AT&T Executive Education and Conference Center, 1900 University Ave.
A new breast cancer staging system developed by researchers at The University of Texas MD Anderson Cancer Center finds that incorporating tumor biology is a critical prognostic indicator for women who undergo neoadjuvant, or pre-surgical, therapy for breast cancer.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right